Drug intelligence / Profile preview

ISH0613

Development stage: Phase 1
Lead developer: SUNHO BioPharmaceutical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ISH0613 is a bifunctional anti-inflammatory bispecific antibody developed by Sunho Biologics (SUNHO (China) BioPharmaceutical Co., Ltd.) for the treatment of inflammatory bowel disease (IBD). It is designed to regulate the immune microenvironment by modulating both the innate and adaptive immune systems. The drug is currently in Phase Ia clinical development, with a first-in-human study evaluating its safety, tolerability, and pharmacokinetics following single intravenous administration in healthy subjects. The specific biological targets of ISH0613 have not been publicly disclosed by the developer.

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on ISH0613.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ISH0613.

Explore the full profile